|Phone||00 1 855-383-7478|
|Description||Personalized medicine company|
Everist Genomics, Inc. (EGI) is a personalized medicine company, which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. EGI is focused on rapidly growing disease areas with major unmet needs, including cancer, cardiovascular disease and metabolic disease (e.g. diabetes). EGI’s innovative products successfully integrate with mobile digital services, smartphones and tablet computers resulting in advanced medical technology, which until now has been confined to the hospital setting.
Mission Everist Genomics is driving growth by developing innovative prognostics with potential for substantive impact on medical and financial outcomes. Our strategy centers on proprietary research and development, targeted acquisitions, and in-licensing. Everist Genomics is currently developing a range of products aimed at improving treatment outcomes in:
• Cancer and Cancer Supportive Care
• Cardiovascular Disease
• Metabolic Disease (e.g. diabetes)
• Neurodegenerative Diseases (e.g. Alzheimer’s and Parkinson’s disease) Description Everist Genomics’ mission is developing and commercializing molecular assays and sensor technology aimed at improving patient outcomes and cost-efficiency through better-informed clinical decisions.
At the core of our success is our evolutionary and proprietary (patent-protected) Evolver technology platform, which accelerates the development of innovative molecular prognostic tests. Utilizing the Evolver technology, Everist Genomics has succeeded in developing a breakthrough colorectal cancer prognostic test (OncoDefender™-CRC), intended to help guide treatment decisions following surgery for Stage I/II colon cancer and Stage I rectal cancer.